Akebia Therapeutics, Inc. (AKBA)
0.6944
+0.02
(+3.64%)
USD |
NASDAQ |
Oct 19, 15:33
Akebia Therapeutics Cash from Operations (Annual) : 67.99M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 67.99M |
| December 31, 2024 | -40.66M |
| December 31, 2023 | -23.38M |
| December 31, 2022 | -73.15M |
| December 31, 2021 | -252.96M |
| December 31, 2020 | -110.39M |
| December 31, 2019 | -257.44M |
| December 31, 2018 | -97.49M |
| Date | Value |
|---|---|
| December 31, 2017 | -56.16M |
| December 31, 2016 | 57.91M |
| December 31, 2015 | -52.41M |
| December 31, 2014 | -27.48M |
| December 31, 2013 | -11.33M |
| December 31, 2012 | -7.211M |
| December 31, 2011 | -14.12M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Emergent BioSolutions, Inc. | 170.60M |
| Exelixis, Inc. | 884.27M |
| ADMA Biologics, Inc. | 50.40M |
| Arcutis Biotherapeutics, Inc. | -5.625M |
| Relay Therapeutics, Inc. | -235.46M |